ChemicalBook > CAS DataBase List > Duvortuxizumab

Duvortuxizumab

Product Name
Duvortuxizumab
CAS No.
1831098-91-9
Chemical Name
Duvortuxizumab
Synonyms
Duvortuxizumab;Research Grade Duvortuxizumab
CBNumber
CB98080991
Formula Weight
0
MOL File
Mol file
More
Less

Duvortuxizumab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Duvortuxizumab Chemical Properties,Usage,Production

Uses

Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E[1].

References

[1] Duvortuxizumab. IMGT.

Duvortuxizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Duvortuxizumab Suppliers

China 9 Global 9
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ：422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Changsha Fuzhen Biotechnology Co.，LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
Country
China
ProdList
10001
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Cell Sciences
Tel
9785721070
Email
info@cellsciences.com
Country
China
ProdList
6308
Advantage
58

1831098-91-9, DuvortuxizumabRelated Search:

Bafisontamab Tarlatamab Alomfilimab Tavolimab Gontivimab Berlimatoxumab Glenzocimab Flotetuzumab Fezakinumab Radretumab

  • Duvortuxizumab
  • Research Grade Duvortuxizumab
  • 1831098-91-9